Cover Image
市場調查報告書

亞太地區的乳癌治療藥市場未來展望:新的HER-2陽性治療方法之治療選擇的多樣化

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

出版商 GBI Research 商品編碼 302278
出版日期 內容資訊 英文
訂單完成後即時交付
價格
Back to Top
亞太地區的乳癌治療藥市場未來展望:新的HER-2陽性治療方法之治療選擇的多樣化 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
出版日期: 2014年05月12日 內容資訊: 英文
簡介

亞太地區各國(印度、澳洲、中國、日本)的乳癌治療藥的市場,2013年達15億美元,2020年預計為25億美元。還有其間的年複合成長率(CAGR)推算為7.6%。在各國中,2013年階段日本的8億7200萬美元為最大,中國為3億2000萬美元,澳洲為2億3400萬美元,印度為8100萬美元。現在,以HER-2遺傳基因為目標的治療藥為首,許多的治療藥正進行開發。臨床實驗中的分子612種類中,臨床實驗前及第一階段為42%,第二階段16%,第三階段8%。

本報告提供亞太地區各國的乳癌治療方法的相關市場相關分析、疾病概要和主要治療模式、已上市產品概要(安全性、功效等)、現在正在開發的治療藥的開發平台資訊、地區整體及主要國的市場趨勢預測(今後8年的預測值)、資本交易、產業聯盟的動向等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 乳癌
  • 症狀
  • 流行病學
  • 病理生理學
  • 診斷
  • 治療後與病期:分類法
  • 治療選擇
    • 外科手術及放射治療
    • 化療
    • 荷爾蒙療法
    • 標靶治療
    • 對藥物療法的抵抗性
    • 治療的指南
    • 治療有效性的測量

第3章 已上市產品

  • 主要的已上市產品
    • Herceptin
    • haraven
    • Avastin
    • Gemzar
    • 克癌易(Taxotere)
    • Tykerb
    • Femara
    • Aromasin
    • Zoladex
    • 瑞寧得(Afatinib)
  • 已上市產品的熱圖(功效、安全性比較分析)

第4章 開發平台分析

  • 開發平台的整體情形
  • 各分子種類的分析
  • 各行動機制分析
  • 臨床實驗的失敗率
  • 臨床實驗的規模
  • 臨床實驗期間
  • 開發平台上有前途的候補藥
    • Buparlisib
    • Palbociclib
    • Afatinib dimaleate
    • Entinostat
    • Neratinib
    • BMN-673
    • Etirinotecan pegol

第5章 市場趨勢的預測(今後8年份)

  • 亞太地區市場
    • 治療方法的利用模式
    • 年度治療費用
    • 市場規模
  • 印度
  • 澳洲
  • 中國
  • 日本
  • 市場促進、阻礙因素

第6章 資本交易、策略性企業聯盟的動向

  • 授權合約
  • 共同開發契約

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC331MR

GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC breast cancer market from 2013 to 2020
  • Major marketed products in the APAC region along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region's breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts business intelligence provider GBI Research.

According to the company's latest report*, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

Saurabh Sharma, Analyst for GBI Research, says: "The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab."

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer's palbociclib and neratinib, and Boehringer Ingelheim's afatinib, will also contribute.

Sharma continues: "The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies."

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to GBI Research.

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

This report analyzes treatment usage patterns, market characterization, pipeline analysis, key licensing and co-development deals in the breast cancer therapeutics market in Australia, China, India and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction

  • 2.1. Breast Cancer
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Prognosis and Disease Staging
    • 2.6.1. Classification
  • 2.7. Treatment Options
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Chemotherapy
    • 2.7.3. Hormonal Therapies
    • 2.7.4. Targeted Therapies
    • 2.7.5. Resistance to Pharmacological Therapies
    • 2.7.6. Treatment Guidelines
    • 2.7.7. Measuring the Effectiveness of Treatment

3. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Herceptin
    • 3.1.2. Halaven
    • 3.1.3. Avastin
    • 3.1.4. Gemzar
    • 3.1.5. Taxotere
    • 3.1.6. Tykerb
    • 3.1.7. Femara
    • 3.1.8. Aromasin
    • 3.1.9. Zoladex
    • 3.1.10. Arimidex
  • 3.2. Heat Map for Marketed Products

4. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Pipeline Analysis

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials - Failure Rate
  • 4.5. Clinical Trial Size
  • 4.6. Duration
  • 4.7. Promising Drug Candidates in Pipeline
    • 4.7.1. Buparlisib
    • 4.7.2. Palbociclib
    • 4.7.3. Afatinib dimaleate
    • 4.7.4. Entinostat
    • 4.7.5. Neratinib
    • 4.7.6. BMN-673
    • 4.7.7. Etirinotecan pegol

5. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020

  • 5.1. Asia-Pacific Market
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Market Size
  • 5.2. India
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Australia
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed and Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Pre-Registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Asia-Pacific
    • 7.2.2. India
    • 7.2.3. Australia
    • 7.2.4. China
    • 7.2.5. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
  • Table 2: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013
  • Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
  • Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013
  • Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013
  • Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
  • Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013
  • Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013
  • Table 9: Market for Breast Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013-2020
  • Table 10: Market for Breast Cancer Therapeutics, India, Forecast Data, 2013-2020
  • Table 11: Market for Breast Cancer Therapeutics, Australia, Forecast Data, 2013-2020
  • Table 12: Market for Breast Cancer Therapeutics, China, Forecast Data, 2013-2020
  • Table 13: Market for Breast Cancer Therapeutics, Japan, Forecast Data, 2013-2020

List of Figures

  • Figure 1: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013
  • Figure 2: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013
  • Figure 3: Breast Cancer Therapeutics Market, Global, Heat Map (Marketed Products)
  • Figure 4: Breast Cancer Therapeutics Market, Global, Pipeline by Stage of Development and Program Type, 2013
  • Figure 5: Breast Cancer Therapeutics Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 6: Breast Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2013
  • Figure 7: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Size (Participants), 2013
  • Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration (months), 2013
  • Figure 10: Breast Cancer Therapeutics Market, Market Size ($m), 2013-2020
  • Figure 11: Breast Cancer Therapeutics Market, India, Market Size ($m), 2013-2020
  • Figure 12: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2013-2020
  • Figure 13: Breast Cancer Therapeutics Market, China, Market Size ($m), 2013-2020
  • Figure 14: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2013-2020
  • Figure 15: Breast Cancer Therapeutics Market, Global, Licensing Agreements, 2006-2013
  • Figure 16: Breast Cancer Therapeutics in APAC Market to 2020, Global, Licensing Agreements, 2006-2013
  • Figure 17: Breast Cancer Therapeutics in APAC Market to 2019, Global, Licensing Agreements, 2006-2013
  • Figure 18: Breast Cancer Therapeutics APAC Market to 2019, Global, Co-Development Deals, 2006-2013
  • Figure 19: Breast Cancer in APAC Market to 2019, Global, Co-Development Agreements, 2006-2013
  • Figure 20: GBI Research Market Forecasting Model
Back to Top